But, brusatol is an Nrf2 inhibitor of natural origin significantly upregulated the FN3K expression in both BT-474 and T4-7D cells (S3 Fig) indicating the combinatorial implications of both FN3K and Nrf2 inhibitors in breast cancers by examining Nrf2-glycation patterns. This evidence concerns the gene FN3K and breast carcinoma.